We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current KRBP market cap is 1.55M. The company's latest EPS is USD -13.5512 and P/E is -0.07.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -3.71M | -19.2M | -25.31M | -31.11M | -19.94M |
| Net Income | -3.73M | -19.2M | -25.59M | -34.73M | -20.95M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.65M | 12.83M | 30.73M | 11.97M | 12.17M |
| Total Liabilities | 674k | 1.47M | 3.41M | 17.74M | 21.29M |
| Total Equity | 1.98M | 11.36M | 27.32M | -5.78M | -9.12M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -2.91M | -6.13M | -20.32M | -23.75M | -21.23M |
| Investing | -303k | -1.46M | -1.81M | -4.87M | -207k |
| Financing | 4.76M | 15.81M | 37.34M | 3.9M | 23.99M |
| Market Cap | 1.55M |
| Price to Earnings Ratio | -0.07 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.48 |
| Price to Book Ratio | -0.17 |
| Dividend Yield | - |
| Shares Outstanding | 1.55M |
| Average Volume (1 week) | 2.81k |
| Average Volume (1 Month) | 1.98k |
| 52 Week Change | 325.53% |
| 52 Week High | 3.78 |
| 52 Week Low | 0.18 |
| Spread (Intraday) | 0.85 (60.71%) |
| Company Name | Kiromic BioPharma Inc (QB) |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://kiromic.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
